The partners will study testing rates, repeat biopsies and their complications, and other factors that preclude routine genotyping in NSCLC.

National Government Services' coverage criteria are different from criteria proposed by Palmetto last year, which may impact companies like Foundation Medicine.

The companies have launched a study measuring the clinical and cost benefits of using Foundation Medicine's FoundationOne genomic profiling assay. 

Both companies are using their assays to detect genetic alterations that confer a higher chance of response to the drug in a newly-announced Phase 2 trial.

Younger NSLCL patients may benefit more from broad genomic profiling because they are more likely to have one of several targetable mutations.

The new study will evaluate how different assays measuring PD-L1 expression compare to one another, an issue raised in recently published research.


The results are some of the first published in full demonstrating the validity of Resolution's bias-corrected sequencing approach since the company was launched.

Thermo Fisher Scientific, Illumina, Eli Lilly, Celgene, and Roche/Genentech have committed their expertise and funding to build a lung cancer registry.

Researchers from a SU2C-sponsored study compared tissue biopsy and liquid biopsy for detecting the T790M mutation of the EGFR gene in a cohort of NSCLC patients.

FDA has approved BMS' Opdivo with a test to guide treatment strategies, but according to the drug label testing isn't required to identify who should receive the drug.


Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.